Tasigna Superior to Gleevec for Philadelphia Chromosome-Positive CML

Tasigna® (nilotinib) is superior to Gleevec® (imatinib) for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML), according to the results of two studies presented at the 54th Annual Meeting of the American Society of Hematology in Atlanta, … Continue reading →

Quizartinib Shows Promise in Treatment-Resistant AML

The targeted agent quizartinib showed promise in the treatment of a subset of patients with treatment-resistant acute myeloid leukemia (AML), according to the results of a study presented at the 54th Annual Meeting of the American Society of Hematology in … Continue reading →

Diabetes Drug May Help Prevent or Treat Ovarian Cancer

Metformin, a widely prescribed insulin-lowering drug for diabetes, has been associated with survival in ovarian cancer and is worthy of further study, as it may be considered for the prevention or treatment of ovarian cancer, according to the results of … Continue reading →

Exercise Reduces Cancer-Related Fatigue

Aerobic exercise can relieve the fatigue associated with cancer and its treatment, according to an updated systematic review published in The Cochrane Library. Fatigue is one of the most common side effects of cancer and its treatment. There are many factors … Continue reading →

Yearly Mammograms May Not Save Many Lives

Contrary to popular belief, annual mammograms may not save as many lives as once thought—and may even lead to substantial overdiagnosis of breast cancer, according to the results of a study published in the New England Journal of Medicine. A mammogram … Continue reading →

No Increased Risk of Birth Defects in Offspring of Childhood Cancer Survivors

Children born to survivors of childhood cancer do not appear to have an increased risk of birth defects. These results were published in the Journal of Clinical Oncology. Cancer treatment can have a range of reproductive effects. Treatment may result in a loss or reduction of fertility in men and women, and treatments that damage [...]

Nplate Produces Rapid Response in Adults with ITP

Among adults with low platelet counts or bleeding symptoms from primary immune thrombocytopenia (ITP), treatment with Nplate® (romiplostim) produces a rapid increase in platelet counts. These results were presented at the 53rd Annual Meeting of the American Society of Hematology. Thrombocytopenia occurs when platelet levels fall below normal. It can often occur as a direct [...]

Velcade Improves Survival with Multiple Myeloma

Final results from the VISTA trial demonstrate that the addition of Velcade® (bortezomib) to melphalan and prednisone substantially improves overall survival among patients with previously untreated multiple myeloma. These results were presented at the 53rd Annual Meeting of the American Society of Hematology. Multiple myeloma is a cancer of plasma cells. Plasma cells are a [...]

Combined HER2 Treatment Improves Outcome of Advanced Breast Cancer

Among women with metastatic, HER2-positive breast cancer, treatment with a combination of HER2-targeted therapies may produce better outcomes than treatment with only a single HER2-targeted therapy. These results were published in the New England Journal of Medicine and were also presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium. Approximately 20-25% of breast cancers [...]

Afinitor Delays Breast Cancer Progression

Among postmenopausal women with advanced breast cancer that had become resistant to hormonal therapy, the combination of Afinitor® (everolimus) and Aromasin® (exemestane) delayed cancer progression to a greater extent than Aromasin alone. The results of this Phase III clinical trial were presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium. Each year roughly 200,000 [...]